151 related articles for article (PubMed ID: 33483290)
1. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese.
Guaraná M; Soares A; Daumas A; Biasoli I; Solza C
Hematol Transfus Cell Ther; 2022; 44(3):321-327. PubMed ID: 33483290
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
3. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Langlais BT; Mazza GL; Kosiorek HE; Palmer J; Mesa R; Dueck AC
J Hematol; 2021 Oct; 10(5):207-211. PubMed ID: 34804309
[TBL] [Abstract][Full Text] [Related]
4. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA
Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863
[TBL] [Abstract][Full Text] [Related]
5. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
6. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
[TBL] [Abstract][Full Text] [Related]
7. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
8. EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS.
Shumeiko OO; Poluben LO; Klimuk BT; Rybchenko LA; Neumerzhitskaya LV; Verbilenko RM; Frolov SV; Klymenko SV
Probl Radiac Med Radiobiol; 2018 Dec; 23():510-516. PubMed ID: 30582868
[TBL] [Abstract][Full Text] [Related]
9. The personal impact of living with a myeloproliferative neoplasm.
Eppingbroek AAM; Lechner L; Bakker EC; Nijkamp MD; de Witte MA; Bolman CAW
Psychooncology; 2024 Apr; 33(4):e6338. PubMed ID: 38610117
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
Mesa R; Boccia RV; Grunwald MR; Oh ST; Colucci P; Paranagama D; Parasuraman S; Stein BL
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):590-596. PubMed ID: 30122202
[TBL] [Abstract][Full Text] [Related]
11. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206
[TBL] [Abstract][Full Text] [Related]
12. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
[No Abstract] [Full Text] [Related]
13. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.
Mazza GL; Kunze KL; Langlais BT; Kosiorek HE; DeWees TA; Geyer HL; Scherber RM; Mesa RA; Dueck AC
Leuk Lymphoma; 2019 Jul; 60(7):1789-1795. PubMed ID: 30652523
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
15. Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.
Le Gall-Ianotto C; Ficheux AS; Lippert E; Herbreteau L; Rio L; Pan-Petesch B; Misery L; Ianotto JC
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1175-1183. PubMed ID: 36808754
[TBL] [Abstract][Full Text] [Related]
16. Approach to MPN Symptom Assessment.
Geyer H; Mesa RA
Curr Hematol Malig Rep; 2017 Oct; 12(5):381-388. PubMed ID: 28942516
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.
Anderson LA; James G; Duncombe AS; Mesa R; Scherber R; Dueck AC; de Vocht F; Clarke M; McMullin MF
Am J Hematol; 2015 Oct; 90(10):864-70. PubMed ID: 26113113
[TBL] [Abstract][Full Text] [Related]
18. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.
Padilla B; Shields AL; Taylor F; Li X; Mcdonald J; Green T; Boral AL; Lin HM; Akin C; Siebenhaar F; Mar B
Orphanet J Rare Dis; 2021 Oct; 16(1):434. PubMed ID: 34663404
[TBL] [Abstract][Full Text] [Related]
19. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.
Johansson P; Mesa R; Scherber R; Abelsson J; Samuelsson J; Birgegård G; Andréasson B
Leuk Lymphoma; 2012 Mar; 53(3):441-4. PubMed ID: 21883029
[TBL] [Abstract][Full Text] [Related]
20. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Mesa R; Verstovsek S; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Zhen H; Jones MM; Parasuraman S; Li J; Côté I; Habr D; Vannucchi AM
Eur J Haematol; 2016 Aug; 97(2):192-200. PubMed ID: 26608702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
